With the Federal Reserve keeping investors guessing on the path of interest rates and inflation signals sending mixed messages, many readers are looking for stocks that do not swing wildly each time a new data point hits the headlines. This article focuses on larger companies that have shown relatively lower price volatility and solid risk and health metrics, which some investors use as a way to seek steadier exposure when markets are choppy. Ahead, you will find 3 stocks from our low volatility screener that appear positively exposed to the current news backdrop.

KORU Medical Systems (KRMD)

Overview: KORU Medical Systems develops, manufactures, and commercializes subcutaneous infusion systems that allow patients with chronic conditions such as primary and secondary immunodeficiencies and certain blood disorders to receive therapies at home or in clinical settings, primarily through its FREEDOM syringe drivers, HIgH Flo needle sets, and dedicated flow rate tubing.

Operations: KORU Medical Systems generates about US$43.3 million in annual revenue from surgical and medical equipment, with roughly US$31.5 million coming from the United States and US$11.8 million from international markets.

Market Cap: US$177.3 million

KORU Medical Systems appears in the low volatility screener as a medical device company tied to recurring infusion consumables, operating in a segment of healthcare that can behave more steadily when interest rate headlines unsettle other sectors. Recent updates show higher sales with a smaller net loss, and management is aiming for 61% to 63% gross margins. Analyst forecasts indicate a possible return to profitability over the next few years. At the same time, KORU relies entirely on external borrowing for funding and currently reports losses, so execution on margin targets and adherence to debt covenants is important. For investors focused on capital preservation with a healthcare angle, the combination of recurring usage, international expansion, and a valuation that some may view as discounted makes KORU a company that some market participants may choose to watch more closely.

Margins at KORU Medical Systems are trying to move in the right direction, but the real story may sit in how that journey lines up with the DCF valuation analysis for KORU Medical Systems and what that implies for the next chapter.

Vitalhub (TSX:VHI)

Overview: Vitalhub provides software that helps hospitals and health and human service providers manage patient flow, electronic health records, care coordination, and workforce compliance across Canada, the UK, Australia, Western Asia, the US, and other regions.

Operations: Vitalhub generates about CA$119.2 million in revenue from healthcare software, with sales spread across Canada, the United Kingdom, Australia, Western Asia, the United States, and other international markets.

Market Cap: CA$430.2 million

Vitalhub stands out in a period of rate uncertainty because it combines a healthcare focus, recurring software revenue and relatively stable price behaviour, which fits the low volatility theme many investors look for. Recent results show higher revenue and net income. Analysts report expectations for solid earnings and margin growth, supported by government backed digital health spending and a growing suite of hospital and community care solutions. At the same time, a high P/E multiple, reliance on acquisitions that still need integration, usage based revenue exposure and funding through external borrowing add execution and balance sheet risk. For readers looking for steadier healthcare tech exposure, Vitalhub’s mix of growth, recurring contracts and integration questions is the kind of story that may warrant a closer look.

Vitalhub’s accelerating mix of recurring software revenue and hospital adoption raises a key question: how well are future expectations already priced in, and what might the analyst forecasts for Vitalhub be missing about the next leg of this story?

Hamilton Thorne (TSX:HTL)

Overview: Hamilton Thorne supplies precision instruments, lab equipment, consumables, software, and services used in fertility clinics and research labs worldwide, covering everything from IVF workstations and incubators to imaging systems and AI enabled analysis tools. Its products support assisted reproductive technologies, cell biology, and diagnostic workflows used by hospitals, pharmaceutical companies, and academic institutions.

Operations: Hamilton Thorne generates about US$76.3 million in revenue, primarily from sales to the ART, research, and cell biology markets, with demand spread across EMEA, the Americas, and Asia/Pacific.

Market Cap: CA$345.3 million

Hamilton Thorne offers a mix of defensive healthcare exposure and specialist fertility and lab tools that can appeal when Fed policy and inflation headlines keep broader markets on edge. The company is currently unprofitable and relies on higher risk external borrowing. Analysts expect revenue to grow faster than the Canadian market and earnings to move into positive territory within 3 years, helped by cost realignment, stronger gross margins, and expanded distribution in North America and Europe. For investors watching the low volatility screener, an important consideration is whether the current discount to some fair value estimates reflects the funding and execution risks, or whether recent regulatory wins and a higher margin product focus could gradually change how Hamilton Thorne is valued.

Hamilton Thorne’s push toward higher margin products and global fertility demand raises a bigger question: how does the current market view stack up against the analyst forecasts for Hamilton Thorne and what they might be underestimating next?

The three stocks covered here are just a starting point, with the full Low Volatility Stocks screener uncovering 9 more larger companies across utilities, consumer staples, and healthcare that carry similarly compelling narratives for investors who want quieter price swings without giving up on opportunity. If you are curious about what else is on the list, take a look at the Low Volatility Stocks screener.

Use Simply Wall St to identify and analyze the specific catalysts, balance sheet traits, and risk profiles discussed here so you can filter that broader universe into a smaller set of highest conviction low volatility ideas that fits your own approach.

Take Control of Your Investment Journey

If KORU Medical Systems or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before Everyone Else?

Fresh opportunities do not sit still. While others react to yesterday’s headlines, you can scan under the radar for stocks building quiet momentum and approaching breakout territory. Consider acting before they become widely followed.

• Spot resilient income ideas before yields get compressed by latecomers and use the carefully curated 7 dividend fortresses to focus on companies built to keep paying investors.
• Ride powerful infrastructure momentum while it is still under the radar by scanning the curated universe in the 34 power grid technology and infrastructure stocks and zero in on your front runners.
• Explore the next wave of robotics demand and use the hand picked 31 robotics and automation stocks to pinpoint companies building real-world automation solutions before the crowd focuses on them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.